Literature DB >> 33546140

Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.

Neeraj Vij1,2,3.   

Abstract

Cystic fibrosis (CF) is a genetic disease caused by a mutation(s) in the CF transmembrane regulator (CFTR), where progressive decline in lung function due to recurring exacerbations is a major cause of mortality. The initiation of chronic obstructive lung disease in CF involves inflammation and exacerbations, leading to mucus obstruction and lung function decline. Even though clinical management of CF lung disease has prolonged survival, exacerbation and age-related lung function decline remain a challenge for controlling the progressive lung disease. The key to the resolution of progressive lung disease is prognosis-based early therapeutic intervention; thus, the development of novel diagnostics and prognostic biomarkers for predicting exacerbation and lung function decline will allow optimal management of the lung disease. Hence, the development of real-time lung function diagnostics such as forced oscillation technique (FOT), impulse oscillometry system (IOS), and electrical impedance tomography (EIT), and novel prognosis-based intervention strategies for controlling the progression of chronic obstructive lung disease will fulfill a significant unmet need for CF patients. Early detection of CF lung inflammation and exacerbations with the timely resolution will not only prolong survival and reduce mortality but also improve quality of life while reducing significant health care costs due to recurring hospitalizations.

Entities:  

Keywords:  CFTR; COPD; airway; asthma; cystic fibrosis; exacerbation; lung; obstructive lung diseases; precision medicine; prognosis; therapeutics

Year:  2021        PMID: 33546140      PMCID: PMC7913194          DOI: 10.3390/jpm11020096

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  83 in total

1.  Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung.

Authors:  G B Pier; M Grout; T S Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 2.  Cystic fibrosis - an example of personalized and precision medicine.

Authors:  Marianne Skov; Christine Rønne Hansen; Tacjana Pressler
Journal:  APMIS       Date:  2019-02-14       Impact factor: 3.205

3.  Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases.

Authors:  Neeraj Vij; Taehong Min; Manish Bodas; Aakruti Gorde; Indrajit Roy
Journal:  Nanomedicine       Date:  2016-07-02       Impact factor: 5.307

4.  Critical role of CFTR-dependent lipid rafts in cigarette smoke-induced lung epithelial injury.

Authors:  Manish Bodas; Taehong Min; Neeraj Vij
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-03-04       Impact factor: 5.464

Review 5.  Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases.

Authors:  M Bodas; I Tran; N Vij
Journal:  Curr Mol Med       Date:  2012-08       Impact factor: 2.222

6.  Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa.

Authors:  Paola Del Porto; Noemi Cifani; Simone Guarnieri; Enea Gino Di Domenico; Maria A Mariggiò; Francesca Spadaro; Silvia Guglietta; Marco Anile; Federico Venuta; Serena Quattrucci; Fiorentina Ascenzioni
Journal:  PLoS One       Date:  2011-05-18       Impact factor: 3.240

7.  Synthesis and Evaluation of Airway-Targeted PLGA-PEG Nanoparticles for Drug Delivery in Obstructive Lung Diseases.

Authors:  Neeraj Vij
Journal:  Methods Mol Biol       Date:  2020

8.  CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells.

Authors:  Neeraj Vij; Martha O Amoako; Steven Mazur; Pamela L Zeitlin
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-20       Impact factor: 6.914

9.  Steps Toward Cell Therapy for Cystic Fibrosis.

Authors:  Kyung Duk Koh; David J Erle
Journal:  Am J Respir Cell Mol Biol       Date:  2020-07-10       Impact factor: 6.914

Review 10.  Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine.

Authors:  Iwona Pranke; Anita Golec; Alexandre Hinzpeter; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Front Pharmacol       Date:  2019-02-27       Impact factor: 5.810

View more
  2 in total

1.  Sweat Proteomics in Cystic Fibrosis: Discovering Companion Biomarkers for Precision Medicine and Therapeutic Development.

Authors:  Bastien Burat; Audrey Reynaerts; Dominique Baiwir; Maximilien Fléron; Sophie Gohy; Gauthier Eppe; Teresinha Leal; Gabriel Mazzucchelli
Journal:  Cells       Date:  2022-07-31       Impact factor: 7.666

Review 2.  Early Diagnosis and Real-Time Monitoring of Regional Lung Function Changes to Prevent Chronic Obstructive Pulmonary Disease Progression to Severe Emphysema.

Authors:  Tony Jung; Neeraj Vij
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.